CD59‐deficient bone marrow erythroid cells from rats treated with procarbazine and propyl‐nitrosourea have mutations in the Pig‐a gene

• Published in: Environmental and molecular mutagenesis Vol. 61; no. 8; pp. 797 - 806
• Main Authors: Revollo, Javier R., Dad, Azra, Pearce, Mason G., Mittelstaedt, Roberta A., Casildo, Andrea, Lapidus, Rena G., Robison, Timothy W., Dobrovolsky, Vasily N.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.10.2020; Wiley Subscription Services, Inc
• Subjects: Amino acid sequence; Animals; Antineoplastic Agents - toxicity; Bone marrow; Bone Marrow Cells - drug effects; Bone Marrow Cells - immunology; Carcinogens; CD59 antigen; CD59 Antigens - genetics; Deficient mutant; Erythrocytes; Erythroid cells; Flow cytometry; Genotype & phenotype; glycosyl phosphatidylinositol; Male; Membrane Proteins - genetics; Mutagens; Mutation; Next-generation sequencing; Nitrosourea Compounds - toxicity; Osteoprogenitor cells; Peripheral blood; Phenotypes; Point mutation; Procarbazine; Procarbazine - toxicity; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; red blood cells; sequencing; Swine; red blood cells; glycosyl phosphatidylinositol; flow cytometry; sequencing

Procarbazine (PCZ) and N‐propyl‐N‐nitrosourea (PNU) are rodent mutagens and carcinogens. Both induce GPI‐anchored marker‐deficient mutant‐phenotype red blood cells (RBCs) in the flow cytometry‐based rat RBC Pig‐a assay. In the present study, we traced the origin of the RBC mutant phenotype by analyz...